Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Siliq

Novartis day

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

New post hoc data comes from phase 3 ASCLEPIOS trials

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

- PMLiVE

FDA approves new self-injection administration for Xolair

Drug is approved for asthma and other allergic and inflammatory conditions

- PMLiVE

UPDATE: US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots

An advisory committee to the CDC recommended extending the pause in the US to review additional data

- PMLiVE

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

Trial included patients with pancreatic, colon, breast and salivary cancer

- PMLiVE

Novartis bolsters radioligand therapy pipeline with new licence agreement

Radioligand therapies are a new potential class of precision oncology drugs

- PMLiVE

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

- PMLiVE

Novartis gains EU approval for relapsing MS drug Kesimpta

The drug reduces the number of confirmed relapses in MS patients

- PMLiVE

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Therapy hit both primary endpoints of overall survival and radiographic progression-free survival

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

- PMLiVE

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links